3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
230
Squamous Cell Carcinoma of Head and Neck
139
Head and Neck Neoplasms
131
Lung Neoplasms
117
Esophageal Neoplasms
88
Stomach Neoplasms
84
Uterine Cervical Neoplasms
68
Esophageal Squamous Cell Carcinoma
66
Urinary Bladder Neoplasms
59
Breast Neoplasms
55
Nasopharyngeal Carcinoma
51
Small Cell Lung Carcinoma
46
Carcinoma, Squamous Cell
39
Neoplasm Metastasis
38
Pancreatic Neoplasms
36
Neoplasms
35
Biliary Tract Neoplasms
34
Oropharyngeal Neoplasms
32
Cholangiocarcinoma
32
Ovarian Neoplasms
30
Mesothelioma, Malignant
28
Adenocarcinoma Of Esophagus
28
Lymphoma
25
Carcinoma
24
Adenocarcinoma of Lung
24
Central Nervous System Neoplasms
22
Laryngeal Neoplasms
20
Carcinoma, Ovarian Epithelial
20
Recurrence
19
Lymphoma, Large B-Cell, Diffuse
19
Interventions
ganitumab
1
dalotuzumab
1
cixutumumab
1
Lapatinib
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Insulin-Like Growth Factor I, Resistance To
×
Cisplatin
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled